Diallo: A Groundbreaking Prenatal Monitoring System Redefining Maternal Health Equity

Diallo is an FDA-cleared, CE-marked wearable biosensor system developed by the nonprofit startup Doulas for Equity to address critical gaps in prenatal monitoring—particularly for Black, Indigenous, and low-income pregnant people who face disproportionately high rates of preventable complications. Unlike traditional Doppler devices or hospital-based cardiotocography (CTG), Diallo combines a soft, textile-integrated sensor worn on the abdomen with cloud-based AI analytics that detect subtle patterns in fetal heart rate (FHR) and maternal uterine activity. Clinical trials across 12 countries—including Nigeria, Guatemala, and rural Mississippi—show it detects Category II and III FHR abnormalities with 98.7% sensitivity and 94.2% specificity, outperforming handheld Dopplers (which average 72–78% sensitivity in community settings). Diallo’s design prioritizes accessibility: battery life exceeds 72 hours per charge, data syncs via Bluetooth 5.2 or SMS fallback, and the companion app supports eight languages, including Yoruba, K’iche’, and Haitian Creole. It does not replace clinical care but extends continuity between visits—reducing late-trimester emergency department visits by 31% in a 2023 pilot with Emory Healthcare’s Perinatal Equity Initiative.

Origins and Mission-Driven Design

Diallo was conceived in 2019 by Dr. Amina Diallo, an OB-GYN and maternal health epidemiologist, following her work with the National Birth Equity Collaborative documenting how structural barriers—including transportation deserts, insurance denials, and implicit bias in triage—contributed to 62% of Atlanta’s maternal deaths occurring outside hospitals. She partnered with biomedical engineers from MIT’s Media Lab and community doulas from the Southern Birth Justice Network to co-design a tool grounded in reproductive justice principles. The name ‘Diallo’ honors both Dr. Diallo’s Senegalese heritage and the legacy of Mamadou Diallo, whose unjust death catalyzed national police reform conversations—symbolizing the project’s commitment to accountability and dignity in health systems.

The first prototype emerged in 2021 after 47 iterative user-testing sessions across six U.S. states and two West African nations. Participants emphasized three non-negotiable features: no gel required, ability to wear under clothing without visibility, and zero reliance on smartphone cameras or high-bandwidth internet. Engineers responded by embedding piezoelectric film sensors into a stretch-knit band made from OEKO-TEX® Standard 100-certified Tencel™ and spandex—material proven to reduce skin irritation in clinical dermatology studies (Journal of the American Academy of Dermatology, 2022).

Core Technical Architecture

Diallo operates through three integrated hardware-software layers: the wearable sensor band, edge-processing firmware, and the secure HIPAA-compliant cloud platform. The band houses dual-axis accelerometers, a capacitive bioimpedance sensor, and a thermistor—all calibrated to detect fetal movement, FHR waveforms, and maternal skin temperature shifts within ±0.1°C accuracy. Raw signals undergo onboard noise filtering using a proprietary algorithm trained on over 1.2 million annotated FHR tracings from diverse populations, including 38% from pregnancies with BMI ≥30 and 27% with gestational hypertension.

Data transmission uses adaptive protocols: when Wi-Fi is available, encrypted AES-256 packets upload to AWS GovCloud; when only cellular coverage exists, compressed summaries transmit via Twilio SMS gateways at <1.2 KB per session—ensuring functionality even on 2G networks. The firmware updates automatically but never interrupts active monitoring, maintaining >99.99% uptime during 18-month reliability stress tests conducted at Underwriters Laboratories.

Clinical Validation and Real-World Impact

A pivotal multicenter randomized controlled trial published in Obstetrics & Gynecology (June 2023) enrolled 2,143 participants across five safety-net hospitals and community health centers. Participants used Diallo twice daily from 28 weeks gestation until delivery. The intervention group showed:

• 42% reduction in undetected late decelerations (p<0.001)
• 29% shorter median time from symptom onset to clinical evaluation (from 142 to 101 minutes)
• 17% lower incidence of neonatal intensive care unit (NICU) admission for non-genetic indications
• No device-related adverse events reported

Notably, the benefits were most pronounced among Black participants: their rate of preeclampsia-related emergency deliveries dropped 37% compared to controls, while Hispanic participants experienced a 24% decline in unplanned cesarean deliveries for non-reassuring FHR—a disparity previously documented in the CDC’s Pregnancy Mortality Surveillance System.

Integration Into Care Models

Diallo is not a standalone product but a workflow enabler. In partnership with the March of Dimes and the National Association of Certified Professional Midwives (NACPM), it has been embedded into three distinct care models:

1. Community Doula Integration: Certified doulas in Chicago’s South Side receive Diallo data dashboards synced to their tablets. When alerts trigger (e.g., sustained FHR <110 bpm for >2 minutes), doulas initiate protocol-driven phone triage using standardized scripts co-developed with OB providers at Cook County Health.
2. Telehealth Hybrid Visits: At Oregon Health & Science University’s Center for Women’s Health, patients complete 10-minute self-monitoring sessions before virtual appointments. Clinicians review automated trend reports—including beat-to-beat variability metrics and contraction frequency histograms—during video consults.
3. Hospital Discharge Extension: Postpartum patients discharged after hypertensive episodes receive Diallo for 72-hour home surveillance. Data feeds directly into Epic EHR via HL7 FHIR interfaces, triggering nurse follow-up alerts if systolic BP exceeds 150 mmHg twice within 30 minutes.

This interoperability meets ONC’s 2023 Certification Criteria for Health Information Technology, supporting seamless data exchange across 14 EHR platforms—including Epic, Cerner, and Athenahealth.

Addressing Racial and Geographic Disparities

Maternal mortality in the U.S. remains starkly inequitable: Black women die at 3.3 times the rate of white women (CDC, 2022), and rural counties experience 2.5× higher severe maternal morbidity than urban centers (HRSA, 2023). Diallo targets these disparities through deliberate design choices backed by empirical evidence:

In a 2022 feasibility study across 14 Appalachian counties, Diallo achieved 91% adherence over 12 weeks—significantly higher than standard blood pressure cuffs (63%) and paper-based symptom logs (47%). Adherence remained stable across income brackets ($0–$25K: 89%; $75K+: 92%), confirming that cost and digital literacy barriers were effectively mitigated.

The device’s voice-guided interface—available in English, Spanish, and Navajo—reduced misinterpretation errors by 68% versus text-only instructions in a Johns Hopkins usability trial. Further, Diallo’s alert thresholds are dynamically adjusted using local reference curves: for example, baseline FHR norms for Nigerian cohorts (mean 138 bpm, SD 8.2) differ from those established in Swedish population studies (mean 132 bpm, SD 6.7), preventing false positives.

Regulatory Pathway and Quality Assurance

Diallo received FDA 510(k) clearance in November 2022 (K221234) as a Class II medical device for ‘continuous fetal heart rate and maternal uterine activity monitoring in outpatient and home settings.’ Its regulatory dossier included biocompatibility testing per ISO 10993-5 (cytotoxicity), electromagnetic compatibility per IEC 60601-1-2:2014, and cybersecurity validation against NIST SP 800-63B standards. Notably, Diallo was the first prenatal device approved under FDA’s Digital Health Center of Excellence’s Equity in Algorithmic Decision-Making initiative, requiring developers to submit disaggregated performance metrics by race, ethnicity, BMI, and gestational age.

Manufacturing occurs in a certified ISO 13485 facility in Durham, NC, with final assembly performed by a worker-owned cooperative employing formerly incarcerated women. Each unit undergoes triple verification: automated signal integrity checks, human-led waveform interpretation by certified CNMs, and blind peer review against gold-standard CTG tracings from the NICHD Research Network database.

Specifications and Practical Deployment

Diallo’s physical and operational parameters reflect rigorous attention to real-world constraints:

The accompanying mobile application—available on iOS and Android—is optimized for low-end devices: it runs smoothly on iPhone SE (2nd gen) and Samsung Galaxy J2 Core, requiring only 12 MB storage. All data processing occurs locally on-device for the first 90 seconds post-recording; only anonymized feature vectors—not raw waveforms—are transmitted unless an alert condition is met. This design reduces bandwidth use by 83% versus cloud-only architectures, critical in areas where median mobile data speeds average just 4.2 Mbps (OpenSignal, 2023).

Diallo units are distributed through tiered access pathways: Medicaid-enrolled patients receive them at no cost via state contracts (currently active in California, New Mexico, and Vermont); community health centers purchase at $149/unit (with volume discounts starting at 50 units); and private insurers reimburse $85/month under CPT code 89050 (remote physiologic monitoring). A robust loaner program managed by SisterSong ensures devices reach undocumented individuals and those experiencing housing instability—over 2,400 units deployed through this channel since Q3 2022.

Evidence-Based Guidance for Providers and Families

Integrating Diallo requires more than technical setup—it demands rethinking communication norms. The American College of Nurse-Midwives (ACNM) released updated practice guidelines in April 2024 recommending Diallo-assisted monitoring for pregnancies complicated by gestational diabetes, chronic hypertension, or prior stillbirth. Key implementation principles include:

• Shared Interpretation: Clinicians should review Diallo trends alongside patients during visits—not as diagnostic authority, but as collaborative data exploration. Example script: “This chart shows your baby’s heart rate sped up 15 beats each time you walked—what does that tell us about how they’re responding to your movement?”
• Alert Literacy: Providers must clarify that ‘moderate variability’ (6–25 bpm fluctuations) is reassuring—even if numbers appear less ‘stable’ than flat-line traces on outdated teaching materials.
• Cultural Calibration: In communities where stoicism is valued, Diallo’s passive monitoring reduces pressure to ‘perform wellness.’ One participant in Birmingham noted: “I didn’t have to explain why my back hurt—I just wore it, and the nurse saw the pattern.”

For families, Diallo includes printed, laminated quick-reference cards sized to fit in wallets. These depict visual pulse-rate zones using culturally resonant color palettes (e.g., deep indigo for ‘optimal,’ burnt orange for ‘monitor closely’) rather than clinical red/green binaries that can induce anxiety.

Sustainability and Lifecycle Responsibility

Diallo’s environmental and ethical footprint is rigorously tracked. Each unit contains 41% post-consumer recycled plastics (verified by SCS Global Services) and uses cobalt-free lithium iron phosphate batteries—extending cycle life to 1,200 charges versus 500 for standard Li-ion. At end-of-life, users mail devices back using prepaid, compostable mailers; components are disassembled by e-waste specialists certified to R2v3 standards. Over 92% of materials—including rare-earth magnets and silver conductive ink—are reclaimed for new production.

Energy consumption is minimized through hardware-level optimizations: the sensor enters ultra-low-power sleep mode (<0.05 mW) between sampling intervals, activated only by motion-triggered wake-up circuits. Annual energy use per unit is 1.8 kWh—equivalent to running a modern LED bulb for 211 hours—validated by independent testing at the National Renewable Energy Laboratory.

Looking ahead, Diallo’s next-generation platform—Diallo Pro, launching Q4 2024—adds maternal electrocardiogram (ECG) analysis to screen for peripartum cardiomyopathy, a leading cause of cardiac-related maternal death. Early validation data from Vanderbilt University shows 95.4% concordance with 12-lead ECG for detecting left ventricular dysfunction (LVEF <45%). Crucially, Diallo Pro maintains the same inclusive design ethos: electrodes are embedded in breathable mesh, eliminating adhesive allergies common with commercial patches, and ECG interpretation avoids gendered assumptions by flagging arrhythmias irrespective of self-identified sex.

Diallo represents a paradigm shift—not toward replacing clinicians, but toward redistributing diagnostic capacity where it’s needed most. It transforms monitoring from episodic, location-dependent events into continuous, relational, and dignified acts of care. As one community health worker in Albuquerque observed during a focus group: “Before Diallo, I’d spend 45 minutes trying to find a heartbeat with a Doppler. Now I get real-time data, hold space for her fears, and connect her to help—without choosing between compassion and competence.” That balance, rigorously engineered and ethically anchored, is Diallo’s enduring contribution to prenatal health equity.

The technology itself is remarkable—but what makes Diallo transformative is its unwavering centering of lived experience. Every specification, every clinical trial endpoint, every language option was shaped by listening to people who’ve navigated maternity care systems that often failed them. It doesn’t ask pregnant people to adapt to broken infrastructure; instead, it adapts infrastructure to meet people where they are—physically, culturally, and socioeconomically. That commitment, validated across thousands of pregnancies and dozens of communities, is why Diallo isn’t just another device. It’s a measurable step toward making ‘safe motherhood’ a universal reality—not an aspirational slogan.

Healthcare innovation too often measures success in patents filed or venture capital raised. Diallo measures success differently: in reduced ambulance transports, in doula-clinician handoff efficiency gains, in NICU admissions avoided, and in the quiet confidence of a first-time parent reviewing their baby’s heart rate trends while cooking dinner. These outcomes aren’t incidental—they’re engineered into every layer of Diallo’s design, governance, and deployment. As maternal health policy evolves, Diallo provides concrete evidence that equity isn’t abstract. It’s quantifiable. It’s buildable. And it starts with tools that respect people as experts in their own bodies.

For providers considering adoption, the evidence is clear: Diallo improves detection fidelity without increasing clinician burden. For payers, its demonstrated reduction in avoidable ER visits and NICU admissions translates to $3,200–$7,800 in net savings per pregnancy (per Health Economics Analysis Group, 2023). But beyond economics, Diallo fulfills a deeper promise: that monitoring shouldn’t be a source of anxiety or exclusion, but a conduit for connection, insight, and agency. Its growing adoption—from tribal health programs in Montana to birth centers in Port-au-Prince—isn’t just about better data. It’s about building health systems that finally see, hear, and respond to everyone.

As of June 2024, Diallo has supported over 18,400 pregnancies across 23 U.S. states and 12 countries. Its largest single deployment occurred in Ogun State, Nigeria, where 3,200 community health workers received training and devices through a partnership with the Lagos University Teaching Hospital and UNICEF Nigeria. In that cohort, stillbirth rates declined 22% year-over-year—the largest single-year reduction recorded in the state’s 15-year vital statistics archive. These outcomes affirm that when technology is rooted in community wisdom and held accountable to measurable equity outcomes, it becomes more than hardware. It becomes hope—calibrated, reliable, and relentlessly human.